Abstract: The present invention relates to diazine and triazine compounds having activity as Interferon and Interleukin inhibitors, particularly Interferon-gamma, Tumour necrosis factor (TNF)-? and Interleukin-1?, 2, 4, 6, 8, 13 and 17 inhibitors, and to the compounds for use in the treatment of cytokine storm syndrome or cytokine release syndrome.

Abstract: An apparatus, method and computer program is described, comprising: rotating a rotatable frame within a liquid provision chamber; providing liquid to a sample on the rotatable frame; obtaining a plurality of images of the sample from a plurality of angles over a first time period; and obtaining a three-dimensional model of the sample based on said plurality of images, wherein the three-dimensional model of the sample comprises quantitative information regarding at least one effect on the sample over the first time period in response to the provision of the liquid.

Abstract: The invention relates to liposomes, methods of producing liposomes, and methods of loading cell-derived liposomes with cargo molecules. The invention extends to such liposomes per se, and to the use of these liposomes as cellular delivery systems for the delivery of biologically and therapeutically active payload molecules, such as small molecules, RNAi molecules (e.g. siRNA), bioactive proteins, genome editing tools (e.g. Cas9) and drugs into cells for treating a range of disorders. The liposomes may also be used in a range of diagnostic and theranostic applications. The invention extends to pharmaceutical compositions comprising such liposomes, including populations of extracellular vesicles (EV), exosomes and to fusion proteins.

Abstract: An insect trap (100) and method for trapping and/or killing insects are disclosed. The insect trap comprises an enclosure (10) for receiving a human or an animal, and comprising an opening (12) configured to allow air to flow out of the enclosure and prevent insects from entering the enclosure, and a trapping unit (30) outside of the enclosure and in fluidic communication with the opening. The trapping unit comprises a heatable container (32) comprising either an adhesive material (31) for attracting and trapping an insect or a material comprising insecticide for killing an insect.

Abstract: The invention relates to a process of preparing a salt of an active pharmaceutical ingredient, the process comprising providing a blend of an active pharmaceutical ingredient and a salt forming substance, mixing the blend, optionally in the presence of added water, to react the active pharmaceutical ingredient with the salt forming substance to provide the salt of the active pharmaceutical ingredient; wherein when the active pharmaceutical ingredient is acidic, the salt forming substance is a base and the pKa difference between the acidic active pharmaceutical ingredient and the base is greater than 1, typically greater than 2 or preferably greater than 3; or when the active pharmaceutical ingredient is basic, the salt forming substance is an acid and the pKa difference between the basic active pharmaceutical ingredient and the acid is greater than 1, typically greater than 2 or preferably greater than 3.

Abstract: The present invention relates to interferon-gamma (IFN-?) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-? production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof.

Abstract: The invention provides a method of manufacturing a stent (12) using a three dimensional (3D) printer. The invention also extends to 3D printed stents and second medical uses of such stents. The invention also extends to electric signals carrying computer-executable instructions adapted to cause a 3D printer to print a stent, computer-readable programs and computer-readable mediums.

Abstract: The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs). Hybrid ASOs, part single-stranded and part double-stranded, are provided, hybridizing to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions. In this way, ASO::protein complexes may be produced that facilitate delivery of antisense DNA into target cells. Such complexes may be used to down-regulate gene expression in cells.

Abstract: Secondary aggregates are prepared from inert waste fines, from, for example, quarrying and combustion processes, using a combination of accelerated carbonation and tumbling, such that aggregate particles composed of successive layers of solid carbonate-based reaction products form a hard aggregate suitable for use in concrete. The process may carried out by loading the starting materials, and if necessary, water into a cylindrical drum that is rotatable about its horizontal axis, and the interior is charged with a carbon dioxide atmosphere, or mounted within a larger vessel that holds a carbon dioxide atmosphere. Aggregates are formed as coatings on core particles as tumbling proceeds, and the coatings are hardened by in situ formation of carbonates by reaction with the carbon dioxide.

Abstract: The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs). Hybrid ASOs, part single-stranded and part double-stranded, are provided, hybridising to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions. In this way, ASO::protein complexes may be produced that facilitate delivery of antisense DNA into target cells. Such complexes may be used to down-regulate gene expression in cells.

Abstract: The invention provides a method of manufacturing a stent (12) using a three dimensional (3D) printer. The invention also extends to 3D printed stents and second medical uses of such stents. The invention also extends to electric signals carrying computer-executable instructions adapted to cause a 3D printer to print a stent, computer-readable programs and computer-readable mediums.

Abstract: The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs). Hybrid ASOs, part single-stranded and part double-stranded, are provided, hybridizing to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions. In this way, ASO::protein complexes may be produced that facilitate delivery of antisense DNA into target cells. Such complexes may be used to down-regulate gene expression in cells.

Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: A method of treating a disorder such as epilepsy, multiple sclerosis, glaucoma and uveitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia, or trigeminal autonomic cephalalgias. The method includes administering to a subject in need thereof substituted 1,2,4-triazine compounds of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: An attractant composition suitable for attracting Lepidopterous insects, particularly Helicoverpa armigera, for use as an insect lure in a control method aimed at reducing pest damage to crops. The preferred attractant composition comprises phenylacetaldehyde, salicylaldehyde and at least one compound selected from the group comprising: methyl-2-methoxybenzoate, linalool and limonene.

Abstract: Microneedle devices are spray coated by nozzles which jet dispense dots onto the individual needles of a microneedle device from a spray nozzle which is angled with respect to the plane of the microneedle device. An angle of between 70° and 45° is preferred and can be achieved by providing the microneedle devices on a support which is inclined at 20° to 45° to the horizontal and using a spray nozzle with a vertical axis.

Abstract: The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs). Hybrid ASOs, part single-stranded and part double-stranded, are provided, hybridising to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions. In this way, ASO::protein complexes may be produced that facilitate delivery of antisense DNA into target cells. Such complexes may be used to down-regulate gene expression in cells.

Abstract: A method of identifying the biotype (or clade) of a whitefly comprising using at least one of: (a) an hsp90 gene, polypeptide or protein, (b) an enolase gene, polypeptide or protein, (c) a fructose bisphosphate aldolase gene, polypeptide or protein, (d) a triose phosphate isomerase gene, polypeptide or protein, or (e) a vitellogenin gene, polypeptide or protein, of the whitefly. A kit for identifying B. tabaci biotype Asia is also provided as well as isolated polynucleotides and polypeptides having SEQ ID 10 NOs: 1-9, and polynucleotides and antibodies that bind SEQ ID NOs: 1-9.

Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: in which R1 is a halo-alkyl group and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system, or a pharmaceutically acceptable salt or solvate thereof.